Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain
tumor in adults. Current treatment options typically consist of surgery followed by …

TROP-2 is a glycoprotein first described as a surface marker of trophoblast cells, but
subsequently shown to be increased in many solid cancers, with lower expression in certain …

Purpose Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a
potential target for antibody-drug conjugates. Sacituzumab govitecan, an antibody-drug …

Trop2 is a transmembrane glycoprotein and calcium signal transducer with limited
expression in normal human tissues. It is consistently overexpressed in a variety of …

Trop-2 is a novel target for ADC therapy because of its high expression by many solid
cancers. The rational development of IMMU-132 represents a paradigm shift as an ADC that …

Chimeric antigen receptor T cells (CAR T cells) are engineered cells expressing a chimeric
antigen receptor (CAR) against a specific tumor antigen (TA) that allows for the identification …

Trop2 is a transmembrane glycoprotein encoded by the Tacstd2 gene. It is an intracellular
calcium signal transducer that is differentially expressed in many cancers. It signals cells for …

Abstract Purpose: Sacituzumab govitecan (IMMU-132) is an antibody–drug conjugate (ADC)
targeting Trop-2, a surface glycoprotein expressed on many epithelial tumors, for delivery of …

Sacituzumab govitecan (IMMU-132) is an antibody–drug conjugate (ADC) made from a
humanized anti-Trop-2 monoclonal antibody (hRS7) conjugated with the active metabolite of …

Injection of tumor cells in mice more than 30years ago resulted in the discovery of an
epithelial antigen, later defined as a cell adhesion molecule (EpCAM). Although EpCAM has …